The analgesic and anti‐inflammatory effects of Salvinorin A analogue β‐tetrahydropyran Salvinorin B in mice

Drugs activating the mu opioid receptor are routinely used to treat severe acute and chronic pain. Unfortunately, side effects including nausea, constipation, respiratory depression, addiction and tolerance can limit clinical utility. In contrast, kappa opioid receptor (KOPr) agonists, such as Salvinorin A (SalA), have analgesic properties with little potential for abuse.

[1]  A. Kaye,et al.  Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys. , 2016, Journal of pharmacological sciences.

[2]  R. Capasso,et al.  The hallucinogenic diterpene salvinorin A inhibits leukotriene synthesis in experimental models of inflammation. , 2016, Pharmacological research.

[3]  G. Pasternak,et al.  Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior. , 2015, ACS chemical neuroscience.

[4]  Xiaowu Hu,et al.  Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation , 2015, Acta Pharmacologica Sinica.

[5]  K. Mackie,et al.  Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1–Dependent Withdrawal , 2015, Biological Psychiatry.

[6]  T. Prisinzano,et al.  Pharmacology and anti‐addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long‐acting analogue of salvinorin A , 2015, British journal of pharmacology.

[7]  B. Roth,et al.  The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[8]  A. Abd-Elsayed,et al.  Study of chronic orofacial pain with preclinical models , 2014, Molecular Pain.

[9]  Cyril Bories,et al.  A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments , 2014, Molecular pain.

[10]  Tony O’Brien,et al.  The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care , 2013, BMC Public Health.

[11]  Y. Ueno,et al.  One year long-term study on abuse liability of nalfurafine in hemodialysis patients. , 2013, International journal of clinical pharmacology and therapeutics.

[12]  H. Loh,et al.  Opioid receptors: toward separation of analgesic from undesirable effects. , 2013, Trends in biochemical sciences.

[13]  B. Cohen,et al.  Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans , 2012, Biological Psychiatry.

[14]  Patrick Richard,et al.  The economic costs of pain in the United States. , 2012, The journal of pain : official journal of the American Pain Society.

[15]  P. Herst,et al.  Indigenous New Zealand honeys exhibit multiple anti-inflammatory activities , 2012, Innate immunity.

[16]  W. MacNaughton,et al.  Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors* , 2012, Inflammatory bowel diseases.

[17]  T. Prisinzano,et al.  A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats , 2012, Behavioural pharmacology.

[18]  L. Bohn,et al.  Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. , 2012, Drug and alcohol dependence.

[19]  R. Capasso,et al.  Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection , 2012, Molecular pain.

[20]  M. Narita,et al.  The kappa opioid receptor agonist SA14867 has antinociceptive and weak sedative effects in models of acute and chronic pain. , 2011, European journal of pharmacology.

[21]  J. Douglas,et al.  Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. , 2011, MedChemComm.

[22]  R. Capasso,et al.  Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo , 2011, Journal of Molecular Medicine.

[23]  C. Goicoechea,et al.  Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats , 2010, Pharmacology Biochemistry and Behavior.

[24]  T. Prisinzano,et al.  Kappa opioids and the modulation of pain , 2010, Psychopharmacology.

[25]  T. Prisinzano,et al.  Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats , 2009, Pharmacology Biochemistry and Behavior.

[26]  T. Rubino,et al.  Potential anxiolytic‐ and antidepressant‐like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents , 2009, British journal of pharmacology.

[27]  T. Prisinzano,et al.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  E. Butelman,et al.  Unconditioned Behavioral Effects of the Powerful κ-Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  S. Husbands,et al.  Effects of Atypical κ-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.

[30]  A. Hohmann,et al.  Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[31]  T. Meert,et al.  Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H. , 2008, Basic & clinical pharmacology & toxicology.

[32]  Joanna S. Fowler,et al.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans , 2008, NeuroImage.

[33]  B. Kuehn.  Prescription drug abuse rises globally. , 2007, JAMA.

[34]  J. Erlichman,et al.  The antinociceptive effect of salvinorin A in mice. , 2006, European journal of pharmacology.

[35]  B. Collett,et al.  Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.

[36]  D. Walsh,et al.  The Adverse Effects of Morphine: A Prospective Survey of Common Symptoms During Repeated Dosing for Chronic Cancer Pain , 2006, The American journal of hospice & palliative care.

[37]  I. Bileviciute-Ljungar,et al.  Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. , 2006, Rheumatology.

[38]  Nora D Volkow,et al.  Major increases in opioid analgesic abuse in the United States: concerns and strategies. , 2006, Drug and alcohol dependence.

[39]  Christopher R. McCurdy,et al.  Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist , 2006, Pharmacology Biochemistry and Behavior.

[40]  T. Prisinzano.  Psychopharmacology of the hallucinogenic sage Salvia divinorum. , 2005, Life sciences.

[41]  P. Dougherty,et al.  Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients , 2004, Pain.

[42]  Bryan L Roth,et al.  Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional Considerations , 2004, Journal of Pharmacology and Experimental Therapeutics.

[43]  Philip S. Portoghese,et al.  Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  Robert G Carlson,et al.  Probable relationship between opioid abuse and heroin use. , 2003, American family physician.

[45]  Bryan L. Roth,et al.  Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Rivière,et al.  Analgesic and Antiinflammatory Effects of Two Novel &kgr;-Opioid Peptides , 2001, Anesthesiology.

[47]  Marc G. Caron,et al.  μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.

[48]  J. Kamei,et al.  Characterization of the antinociceptive effects of TRK-820 in the rat. , 2000, European journal of pharmacology.

[49]  M. Narita,et al.  Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist , 1999 .

[50]  H. Nagase,et al.  Pharmacological properties of TRK-820 on cloned μ-, δ- and κ-opioid receptors and nociceptin receptor , 1999 .

[51]  B. Roques,et al.  Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.

[52]  M. J. van den Bent,et al.  Progression of paclitaxel‐induced neuropathy following discontinuation of treatment , 1997, Muscle & nerve.

[53]  Judith S. Walker,et al.  The site of anti‐arthritic action of the K‐opioid, U‐50,488H, in adjuvant arthritis: importance of local administration , 1996, British journal of pharmacology.

[54]  L J Valdés,et al.  Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. , 1994, Journal of psychoactive drugs.

[55]  E K Rowinsky,et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[57]  A. Forman.  Peripheral neuropathy in cancer patients: clinical types, etiology, and presentation. Part 2. , 1990, Oncology.

[58]  R. Dubner,et al.  Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding , 1988, Pain.

[59]  G. Di Chiara,et al.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[60]  T. Shippenberg,et al.  Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of μ- and κ-opioid agonists , 1987, Brain Research.

[61]  V. Hruby,et al.  Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. , 1984, The Journal of pharmacology and experimental therapeutics.

[62]  José-Luis Díaz,et al.  Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). , 1983, Journal of ethnopharmacology.

[63]  E. Freye,et al.  Bremazocine: An Opiate That Induces Sedation and Analgesia without Respiratory Depression , 1983, Anesthesia and analgesia.

[64]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[65]  M. Kainoh,et al.  Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys. , 2016, Journal of pharmacological sciences.

[66]  E. Carstens,et al.  Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. , 2015, Acta dermato-venereologica.

[67]  Jon O Ebbert,et al.  Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. , 2013, Mayo Clinic proceedings.

[68]  M. Angst,et al.  Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. , 2006, The journal of pain : official journal of the American Pain Society.

[69]  Iaira Boissevain,et al.  Implications of Research for Treatment: Ghb Latest Research Findings Adverse Effects , 2022 .

[70]  R. Gainetdinov,et al.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. , 2000, Nature.

[71]  M. Narita,et al.  Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. , 1999, Life sciences.

[72]  J. Walker,et al.  Opposite effects of mu and kappa opiates on the firing-rate of dopamine cells in the substantia nigra of the rat. , 1987, European journal of pharmacology.

[73]  T. Shippenberg,et al.  Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. , 1987, Brain research.

[74]  R. Wasson.  A New Mexican Psychotropic Drug from the Mint Family , 1962, Botanical Museum leaflets, Harvard University.

[75]  C. Dohna-Schwake,et al.  Effect of a novel kappa-receptor agonist , nalfurafine hydrochloride , on severe itch in 337 haemodialysis patients : a Phase III , randomized , double-blind , placebo-controlled study , 2022 .